Passera Eliseo, Orlandi Riccardo, Calderoni Matteo, Cassina Enrico Mario, Cioffi Ugo, Guttadauro Angelo, Libretti Lidia, Pirondini Emanuele, Rimessi Arianna, Tuoro Antonio, Raveglia Federico
Department of Thoracic Surgery, San Gerardo Hospital, ASST Monza, Monza, Italy.
Department of Thoracic Surgery, University of Milan, Milan, Italy.
Front Surg. 2023 Feb 13;10:1125997. doi: 10.3389/fsurg.2023.1125997. eCollection 2023.
Iatrogenic tracheobronchial injury (ITI) is an infrequent but potentially life-threatening disease, with significant morbidity and mortality rates. Its incidence is presumably underestimated since several cases are underrecognized and underreported. Causes of ITI include endotracheal intubation (EI) or percutaneous tracheostomy (PT). Most frequent clinical manifestations are subcutaneous emphysema, pneumomediastinum and unilateral or bilateral pneumothorax, even if occasionally ITI can occur without significant symptoms. Diagnosis mainly relies on clinical suspicion and CT scan, although flexible bronchoscopy remains the gold standard, allowing to identify location and size of the injury. EI and PT related ITIs more commonly consist of longitudinal tear involving the pars membranacea. Based on the depth of tracheal wall injury, Cardillo and colleagues proposed a morphologic classification of ITIs, attempting to standardize their management. Nevertheless, in literature there are no unambiguous guidelines on the best therapeutic modality: management and its timing remain controversial. Historically, surgical repair was considered the gold standard, mainly in high-grade lesions (IIIa-IIIb), carrying high morbi-mortality rates, but currently the development of promising endoscopic techniques through rigid bronchoscopy and stenting could allow for bridge treatment, delaying surgical approach after improving general conditions of the patient, or even for definitive repair, ensuring lower morbi-mortality rates especially in high-risk surgical candidates. Our perspective review will cover all the above issues, aiming at providing an updated and clear diagnostic-therapeutic pathway protocol, which could be applied in case of unexpected ITI.
医源性气管支气管损伤(ITI)是一种罕见但可能危及生命的疾病,具有较高的发病率和死亡率。其发病率可能被低估,因为有几例病例未得到充分认识和报告。ITI的病因包括气管插管(EI)或经皮气管切开术(PT)。最常见的临床表现是皮下气肿、纵隔气肿和单侧或双侧气胸,即使偶尔ITI也可能在没有明显症状的情况下发生。诊断主要依靠临床怀疑和CT扫描,尽管可弯曲支气管镜检查仍是金标准,能够确定损伤的位置和大小。与EI和PT相关的ITI更常见的是累及膜部的纵向撕裂。基于气管壁损伤的深度,卡尔迪洛及其同事提出了ITI的形态学分类,试图规范其治疗。然而,文献中对于最佳治疗方式尚无明确的指南:治疗方法及其时机仍存在争议。从历史上看,手术修复被认为是金标准,主要用于高级别病变(IIIa-IIIb),其病死率较高,但目前通过硬质支气管镜和支架置入等有前景的内镜技术的发展,可以进行过渡治疗,在改善患者一般状况后延迟手术,甚至进行确定性修复,尤其在高风险手术候选者中确保较低的病死率。我们的综述将涵盖上述所有问题,旨在提供一个更新且清晰的诊断-治疗路径方案,可应用于意外发生的ITI情况。